Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma

Anticancer Research

Volumn 34, Issue 10, 2014, Pages 5555-5561

  Čermáková, Petra ^a   Melichar, Bohuslav ^a,b   Tomšová, Markéta ^a   Zoul, Zdeněk ^a   Kalábová, Hana ^b   Špaček, Jiří ^a   Doležel, Martin ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Biomarkers; Endometrial carcinoma; Tumor associated macrophages; Tumor infiltrating lymphocytes.

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLEAR CELL CARCINOMA; EARLY CANCER; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; AGED; CANCER GRADING; CELL COUNT; ENDOMETRIAL NEOPLASMS; IMMUNOLOGY; LEUKOCYTE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD3; CELL COUNT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LEUKOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS;

EID: 84917711082     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Creasman VVT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY and Pecorelli S: Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 95: S105-S143, 2006.
2. + tumor-infiltrating lymphocytes in ovarian carcinoma. Gyn Oncol 108: 415-420, 2008.
3. Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H and Ryska A: Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 26: 1024-1031, 2008.
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T-cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
5. +regulatory T-cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer 21: 1628-1634, 2011.
6. Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O and Kikkawa F: Inverse correlation between tumoral indoleamine-2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin Cancer Res 14: 2310-2317, 2008.
7. + T-lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 10: 4450-4456, 2004.
8. de Jong RA, Leffers HM, Boezen HM, ten Hoor KA, van der Zee AGJ, Hollema H and Nijman HW: Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gyn Oncol 114: 105-110, 2009.
9. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gyn Oncol 110: 216-221, 2008.
10. Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gyn Oncol 106: 119-127, 2007.
11. Shia J, Black D, Hummer AJ, Boyd J and Soslow RA: Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Human Pathol 39: 116-125, 2008.
12. Melichar B: Human epididymis protein 4: The start of a post-roman era? Clin Chem Lab Med 50: 2069-2073, 2012.
13. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M and Scambia G: Expression of cyclooxygenase-2 (COX2), receptors for estrogen (ER), and progesterone (PR), p53, Ki67, and neu protein in endometrial cancer. Gyn Oncol 98: 383-389, 2005.
14. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
15. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C, Kavanagh JJ, Hicks ME, Levy LB, Folloder JK and Garcia ME: Pilot study of FLT3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 9: 5228-5237, 2003.
16. Melichar B and Freedman RS: Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 12: 3-17, 2002.
17. Melichar B, Savary CA, Patenia R, Templin S, Melicharova K and Freedman RS: Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 13: 435-443, 2003.
18. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gyn Oncol 109: 122-128, 2008.